AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Bausch Health Companies Inc (NYSE:BHC)
4.95 USD
-0.060 1.198%Sponsored Reports
Loading...
| Previous Close (in USD) | 5.01 |
|---|---|
| Change | -0.060 1.198% |
| 52 W H/L (in USD) | 8.690/4.410 |
| EBITDA (in USD) | 3400M |
| PE Ratio | 13.98 |
| Volume | 2559114 |
| Diluted Eps TTM | 0.41 |
| Total Assets (in USD) | 26318.018M |
|---|---|
| Total Liabilities (in USD) | 25941.704M |
| Revenue TTM (in USD) | 10266M |
| Cash (in USD) | 1322.589M |
| Market Cap (in USD) | 2,139.946 M |
| Revenue Per Share TTM | 27.679 |
| Gross Profit TTM (in USD) | 7253M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Bausch Health Companies Inc
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
2150 St. ElzEar Boulevard West, Laval, QC, Canada, H7L 4A8
514 744 6792
Employees: 20300
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Thomas J. Appio | CEO & Director | 1962 |
| 2. | Mr. Thomas G. Vadaketh | Exec. VP & CFO | 1963 |
| 3. | Mr. Mirza Dautbegovic | Sr. VP & COO | NA |
| 4. | Mr. John S. Barresi | Sr. VP, Controller & Chief Accounting Officer | 1973 |
| 5. | Dr. Robert F. Butz | VP of Medical & Scientific Affairs | NA |
| 6. | Mr. Arthur J. Shannon | Sr. VP and Head of Investor Relations & Global Communications | NA |
| 7. | Ms. Seana Carson | Exec. VP & Gen. Counsel | 1972 |
| 8. | Ms. Kathleen Fitzpatrick | Sr. VP & Chief HR Officer | NA |
| 9. | Dr. Tage Ramakrishna M.D. | Chief Medical Officer and Pres of R&D | 1974 |
| 10. | Mr. Jeff Hartness | Sr. VP of Market Access, Commercial Operations & Gov. Affairs | NA |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ZTS
Zoetis Inc |
+1.200 1.571% | 76.22 | 40.180 | 30.960 | 10.675 | 17.597 | 11.271 | 26.180 |
|
MKKGY
Merck KGaA ADR |
+0.580 1.906% | 30.72 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
|
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
0.000 0.000% | 153.91 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
|
GALDY
GALDERMA GROUP AG |
-0.790 1.894% | 41.335 | 74.210 | 41.667 | 8.636 | 5.553 | 9.151 | 42.220 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | 367.861M | 167M | -390M | -129M | -1024M |
| Minority Interest | 37M | 26M | 19M | -13M | 11M |
| Net Income | 155.278M | -46M | -592M | -212M | -937M |
| Selling General Administrative | 3438M | 2497M | 2270M | 2625M | 2624M |
| Gross Profit | 7044.084M | 6843M | 6198M | 5760M | 6040M |
| Reconciled Depreciation | 1208M | 1267M | 1264M | 1215M | 1375M |
| Ebit | 1882.927M | 1867M | 1621M | 1370M | 1210M |
| Ebitda | 3095.384M | 3134M | 2885M | 2585M | 2585M |
| Depreciation And Amortization | 1212.458M | 1267M | 1264M | 1215M | 1375M |
| Operating Income | 2069.052M | 1546M | 963M | 1370M | 1210M |
| Other Operating Expenses | 8239.926M | 8079M | 7794M | 6768M | 7231M |
| Interest Expense | 1515.066M | 1388M | 1328M | 1464M | 1426M |
| Tax Provision | 247M | 239M | 221M | 83M | -87M |
| Interest Income | 1608M | 33M | 26M | 14M | 7M |
| Net Interest Income | -1556M | -1355M | -1302M | -1450M | -1419M |
| Income Tax Expense | 249.444M | 239M | 221M | 83M | -87M |
| Total Revenue | 10308.978M | 9625M | 8757M | 8124M | 8434M |
| Total Operating Expenses | 4975.032M | 5297M | 5235M | 4404M | 4837M |
| Cost Of Revenue | 3264.894M | 2782M | 2559M | 2364M | 2394M |
| Total Other Income Expense Net | -1701.191M | -1379M | -1353M | -1499M | -2234M |
| Net Income From Continuing Ops | 120M | -72M | -611M | -212M | -937M |
| Net Income Applicable To Common Shares | 157M | -46M | -592M | -225M | -948M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 26318.018M | 26523M | 27350M | 25686M | 29202M |
| Intangible Assets | 4634.55M | 5551M | 6456M | 5800M | 6948M |
| Other Current Assets | 850.449M | 858M | 1107M | 776M | 720M |
| Total Liab | 25941.704M | 26845M | 27432M | 25426M | 29236M |
| Total Stockholder Equity | -552.992M | -1279M | -1022M | -692M | -106M |
| Other Current Liab | 3277.025M | 3359M | 3086M | 2988M | 4791M |
| Common Stock | 10496.862M | 10490M | 10423M | 10391M | 10317M |
| Capital Stock | 10516M | 10490M | 10423M | 10391M | 10317M |
| Retained Earnings | -9649.408M | -9824M | -9778M | -9186M | -8961M |
| Good Will | 11250.488M | 11087M | 11183M | 11547M | 12457M |
| Other Assets | 2006M | - | - | 2271M | 2345M |
| Cash | 1322.589M | 1181M | 947M | 564M | 582M |
| Cash And Equivalents | 1309M | - | - | 564M | 582M |
| Total Current Liabilities | 4172.393M | 6752M | 4302M | 3941M | 5198M |
| Current Deferred Revenue | - | - | 2092M | - | - |
| Net Debt | 19884.747M | 20435M | 21441M | 20202M | 22072M |
| Short Term Debt | 296.46M | 2674M | 450M | 432M | 0M |
| Short Long Term Debt | 225M | 2674M | 450M | 432M | - |
| Short Long Term Debt Total | 21207.335M | 21616M | 22388M | 20766M | 22654M |
| Other Stockholder Equity | 356.35M | 234M | 214M | 159M | 462M |
| Property Plant Equipment | 2289M | - | - | 1821M | 1598M |
| Total Current Assets | 6145.795M | 5774M | 5596M | 4247M | 5607M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 2346.722M | 2140M | 1998M | 1790M | 1775M |
| Long Term Debt | 20592M | 18942M | 21938M | 20334M | 22654M |
| Inventory | 1626.035M | 1595M | 1544M | 1090M | 993M |
| Accounts Payable | 598.908M | 656M | 719M | 521M | 407M |
| Accumulated Other Comprehensive Income | -1756.797M | -2179M | -1881M | -2056M | -1924M |
| Non Currrent Assets Other | 377.312M | 363M | 307M | 326M | 340M |
| Non Current Assets Total | 20172.223M | 20749M | 21754M | 21439M | 23595M |
| Capital Lease Obligations | 34M | - | - | - | - |
| Long Term Debt Total | 20615M | - | - | 20334M | 22654M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | -3M | -454M | -2133M | 5M | -4M |
| Total Cashflows From Investing Activities | -595M | -454M | -2145M | -303M | 409M |
| Total Cash From Financing Activities | -742M | -868M | 1475M | -474M | -1513M |
| Net Income | 120M | -72M | -611M | -212M | -937M |
| Change In Cash | 124M | 239M | 371M | -1528M | 303M |
| Begin Period Cash Flow | 1201M | 962M | 591M | 2119M | 1816M |
| End Period Cash Flow | 1325M | 1201M | 962M | 591M | 2119M |
| Total Cash From Operating Activities | 1400M | 1597M | 1032M | -728M | 1426M |
| Depreciation | 1208M | 1267M | 1264M | 1394M | 1552M |
| Other Cashflows From Investing Activities | -195M | -119M | -39M | -35M | 682M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -12.21M | -267M | -322M | -198M | -16M |
| Sale Purchase Of Stock | - | -26M | -24M | 675M | - |
| Other Cashflows From Financing Activities | -93.849M | -43M | -106M | 6697M | 1927M |
| Capital Expenditures | 397M | 337M | 272M | 268M | 283M |
| Change In Working Capital | -222.834M | 7M | -582M | -396M | -128M |
| Other Non Cash Items | -1.166M | 179M | 778M | -1464M | 1036M |
| Free Cash Flow | 1003M | 1260M | 760M | -996M | 1143M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Loomis Sayles MFD Class C | 5 months ago | 4345000 |
| 2. | Vanguard Total Intl Stock Index Inv | 2 months ago | 3762192 |
| 3. | JPM High Quality High Yield-Composite | 5 months ago | 3723109 |
| 4. | Loomis Sayles Strategic Alpha | 5 months ago | 2600000 |
| 5. | CREF Total Global Stock Account R3 | 3 months ago | 2571986 |
| 6. | Vanguard Developed Markets Index Admiral | 2 months ago | 2447301 |
| 7. | Fidelity Canadian Value ETF | 2 months ago | 2117062 |
| 8. | Fidelity Canadian High Quality ETF | 2 months ago | 1923004 |
| 9. | Vanguard Instl Ttl Intl Stk Mkt Idx TrII | 2 months ago | 1852864 |
| 10. | iShares Core S&P/TSX Capped Compost ETF | 2 months ago | 1487727 |
| 11. | Schwab Fundamental International Eq ETF | 2 months ago | 1394291 |
| 12. | Dimensional Canadian Small Company | 7 months ago | 1387468 |
| 13. | DFA International Small Company I | 3 months ago | 1376619 |
| 14. | Nuveen Quant Intl Small Cap Eq R6 | 3 months ago | 1246985 |
| 15. | Vanguard FTSE All-Wld ex-US SmCp Idx Ins | 2 months ago | 950179 |
| 16. | BLK CDN MSCI Can IMI Ext ESG Fcs Idx A | 2 months ago | 855436 |
| 17. | BMO S&P/TSX Capped Composite ETF | 2 months ago | 839791 |
| 18. | RBC QUBE Canadian Equity F | 5 months ago | 826600 |
| 19. | Vanguard FTSE Canada All Cap ETF | 2 months ago | 793769 |
| 20. | Core Plus Full Discretion CIT D | 5 months ago | 780000 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Paulson & Company Inc | 5 months ago | 73255869 |
| 2. | Goldentree Asset Management LP | 8 months ago | 34833431 |
| 3. | Nomura Holdings Inc | 8 months ago | 15708085 |
| 4. | Vanguard Group Inc | 5 months ago | 10679760 |
| 5. | Royal Bank of Canada | 8 months ago | 10506521 |
| 6. | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 5 months ago | 8452119 |
| 7. | NATIONAL BANK OF CANADA /FI/ | 8 months ago | 7723051 |
| 8. | MFN Partners Management, LP | 5 months ago | 6000000 |
| 9. | Kohlberg Kravis Roberts & Co LP | 5 months ago | 5235000 |
| 10. | UBS Group AG | 8 months ago | 5148450 |
| 11. | The Goldman Sachs Group Inc | 5 months ago | 5143641 |
| 12. | Hudson Bay Capital Management LP | 5 months ago | 5000000 |
| 13. | ING Groep NV | 8 months ago | 5000000 |
| 14. | NORGES BANK | 5 months ago | 3682488 |
| 15. | Dimensional Fund Advisors, Inc. | 5 months ago | 3253995 |
| 16. | Macquarie Group Ltd | 5 months ago | 3250000 |
| 17. | Arrowstreet Capital Limited Partnership | 5 months ago | 2723655 |
| 18. | Charles Schwab Investment Management Inc | 5 months ago | 2045737 |
| 19. | Private Management Group Inc | 5 months ago | 1892895 |
| 20. | Millennium Management LLC | 5 months ago | 1836137 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...